Press

With an $8M seed investment led by The Engine, Droplet will develop a liquid biopsy test using lymphatic fluid rather than blood plasma as a source for detecting cancer-associated DNA alterations.

March 16, 2023

Read the full article on GenomeWeb:

https://www.genomeweb.com/cancer/droplet-biosciences-targets-lymph-fluid-new-residual-cancer-detection-strategy#.ZBMW5-zMKrc